| Literature DB >> 30189892 |
Mekdes Tigistu1, Telake Azale2, Habtamu Kebebe3, Temesgen Yihunie2.
Abstract
OBJECTIVE: About three-fourth of adults with new-onset epilepsy become seizure-free with current anti-epileptic drugs, but around one-fourth of the patients continue to experience seizure which increases the risk of accident, disability, death and treatment side effects. Therefore, this study aimed to address the gap in determining the magnitude of the number of seizure attacks and identify the factors that provoke a repeated seizure in a patient with epilepsy.Entities:
Keywords: Epileptic patient; Frequency; Gondar; Seizure; Zero-Inflated Negative Binomial
Mesh:
Year: 2018 PMID: 30189892 PMCID: PMC6127944 DOI: 10.1186/s13104-018-3761-3
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Socio-demographic, economic and treatment related characteristics of the study participants of seizure frequency and associated factors among patient with epilepsy in University of Gondar Referral Hospital, 2017 (n = 408)
| Variables with category | Frequency | Percentage (%) |
|---|---|---|
| Age | ||
| 15–24 | 175 | 42.89 |
| 25–34 | 123 | 30.15 |
| 35–44 | 49 | 12.01 |
| 45–54 | 24 | 5.88 |
| 55–64 | 25 | 6.13 |
| 65–80 | 12 | 2.94 |
| Sex | ||
| Male | 243 | 59.56 |
| Female | 165 | 40.44 |
| Residence | ||
| Urban | 247 | 60.54 |
| Rural | 161 | 39.46 |
| Marital status | ||
| Single | 233 | 57.11 |
| Married | 138 | 33.82 |
| Divorced | 26 | 6.37 |
| Widowed | 11 | 2.7 |
| Educational level | ||
| No formal education | 158 | 38.72 |
| Primary | 118 | 28.91 |
| Secondary | 79 | 19.36 |
| Higher | 53 | 13 |
| Occupation | ||
| Student | 133 | 32.6 |
| Farmer | 111 | 27.21 |
| Merchant | 33 | 8.09 |
| Employee | 45 | 11.03 |
| Housewife | 50 | 12.25 |
| Other | 36 | 8.82 |
| Wealth index | ||
| Poor | 153 | 37.5 |
| Middle | 146 | 35.78 |
| Rich | 109 | 26.72 |
| Type of drug when treatment started | ||
| Phenobarbital | 255 | 62.5 |
| Phenytoin | 55 | 13.48 |
| Carbamazepine | 15 | 3.68 |
| Two or more drugs | 79 | 19.36 |
| Othera | 4 | 0.98 |
| Adherence | ||
| Low | 100 | 24.57 |
| Moderate | 127 | 31.2 |
| High | 180 | 44.23 |
| Duration of treatment (years) | ||
| < 1 | 52 | 12.75 |
| 1–5 | 204 | 50 |
| 5–10 | 98 | 24.02 |
| > 10 | 54 | 13.23 |
| Treatment modality | ||
| Mono | 308 | 75.49 |
| Poly | 100 | 24.51 |
| Current medication | ||
| Phenobarbital | 253 | 62.01 |
| Phenytoin | 31 | 7.6 |
| Carbamazepine | 13 | 3.19 |
| Two or more drugs | 106 | 25.98 |
| Othera | 5 | 1.22 |
| Tapering in the last 2 months | ||
| Yes | 21 | 5.15 |
| No | 387 | 94.85 |
| Treatment side effect | ||
| Yes | 38 | 9.31 |
| No | 370 | 90.69 |
| Treatment affordability | ||
| Yes | 259 | 63.48 |
| No | 149 | 36.52 |
Other: lamotrigine, sodium valproate and haloperidol
Fig. 1Number of seizure attack in the last 2 months among study participants of seizure frequency and associated factors among patients with epilepsy in University of Gondar Referral Hospital, 2017 (n = 408)
Risk factors of seizure frequency in the last 2 months among patients with epilepsy in University of Gondar Referral Hospital from Zero Inflated Negative Binomial Poisson Regression model, 2017 (n = 408)
| Variables | Seizure frequency | CIRR(95% CI) | AIRR(95% CI) | P-value | ||
|---|---|---|---|---|---|---|
| 0 | 1_5 | ≥ 6 | ||||
| Noise | ||||||
| No | 169 | 80 | 1 | 1 | 1 | < 0.001 |
| Yes | 73 | 76 | 9 | 2.89(2.08, 4.01) | ||
| Light | ||||||
| No | 208 | 108 | 4 | 1 | 1 | 0.011 |
| Yes | 34 | 48 | 6 | 2.33(1.59, 3.41) | ||
| Humidity | ||||||
| No | 234 | 147 | 8 | 1 | 1 | 0.147 |
| Yes | 8 | 9 | 2 | 2.46(1.18, 5.13) | 1.62(0.84, 3.13) | |
| Head injury | ||||||
| No | 238 | 155 | 8 | 1 | 1 | 0.009 |
| yes | 3 | 12 | 2 | 3.50(1.67, 7.34) | ||
| Meal on time | ||||||
| No | 203 | 188 | 6 | 1 | 1 | 0.192 |
| Yes | 39 | 38 | 4 | 1.69(1.12, 2.55) | 1.21(0.90, 1.62) | |
| Sleep deprivation | ||||||
| No | 216 | 213 | 6 | 1 | 1 | 0.035 |
| Yes | 26 | 43 | 4 | 2.21(1.48, 3.36) | ||
| Strenuous exercise | ||||||
| No | 222 | 133 | 6 | 1 | 1 | 0.607 |
| Yes | 20 | 23 | 4 | 1.80(1.09, 2.99) | 1.10(0.76, 1.60) | |
| Side effect | ||||||
| No | 222 | 142 | 6 | 1 | 1 | 0.316 |
| Yes | 20 | 14 | 4 | 1.87(1.08, 3.24) | 1.33(0.76, 2.35) | |
Italics show significance
*** P-value less than 0.001, ** P-value less than 0.01, * P-Value less than 0.05, 1-Reference Category